QS-17 and18 |
|
Vaxjo ID |
395 |
|
Vaccine Adjuvant Name |
QS-17 and18 |
|
Alternative Names |
they are both derived from Quillaja saponaria saponins. |
|
Adjuvant VO ID |
VO_0005677
|
|
Description |
QS-17 and QS-18 are saponin-based adjuvants that enhance immune responses, particularly promoting mixed Th1/Th2 immune responses when used in vaccine formulations. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
We have synthesized a QS-17/18 analogue (7) and evaluated its adjuvant activity in the formulation with rHagB antigen. Compound 7 and QS-21 analogues 5 and 6 are presumably the major components of GPI-0100, a widely used complex mixture of semisynthetic derivatives of Quillaja saponaria (QS) Molina saponins. |
|
Structure |
The structure of QS-17 and QS-18 includes a triterpene core with a branched oligosaccharide domain |
|
Preparation |
QS-17 and QS-18 are prepared through chemical synthesis and derivatization of natural saponins from Quillaja saponaria. |
|
Function |
We have synthesized a QS-17/18 analogue (7) and evaluated its adjuvant activity in the formulation with rHagB antigen. Compound 7 and QS-21 analogues 5 and 6 are presumably the major components of GPI-0100, a widely used complex mixture of semisynthetic derivatives of Quillaja saponaria (QS) Molina saponins |
|
Safety |
QS-17 and QS-18 have shown a favorable safety profile in preclinical studies, but specific safety data in clinical trials are not provided. QS-18 More toxic than QS-21 due to extra β-d-glucopyranosyl (glc) unit connected to the α-L-rhamnopyranosyl (rha) unit at its 3-O position [PMC8001307]. |
| References |
Wang et al., 2019: Wang P, Å kalamera Ä, Sui X, Zhang P, Michalek SM. Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant. Journal of medicinal chemistry. 2019; 62(3); 1669-1676. [PubMed: 30656932].
Wang, 2021: Wang P. Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines. 2021; 9(3); . [PubMed: 33807582].
|
